Open AccessThis article is
- freely available
Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
Rega Institute for Medical Research, KULeuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 15 December 2009; in revised form: 9 March 2010 / Accepted: 17 March 2010 / Published: 29 March 2010
Abstract: Hepatitis C virus (HCV) represents a major health burden, with an estimated 180 million chronically infected individuals worldwide. These patients are at increased risk of developing liver cirrhosis and hepatocellular carcinoma. Infection with HCV is the leading cause of liver transplantation in the Western world. Currently, the standard of care (SoC) consists of pegylated interferon alpha (pegIFN-α) and ribavirin (RBV). However this therapy has a limited efficacy and is associated with serious side effects. Therefore more tolerable, highly potent inhibitors of HCV replication are urgently needed. Both Specifically Targeted Antiviral Therapy for HCV (STAT-C) and inhibitors that are believed to interfere with the host-viral interaction are discussed.
Keywords: HCV; new antivirals; review
Citations to this Article
Cite This Article
MDPI and ACS Style
Delang, L.; Coelmont, L.; Neyts, J. Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses 2010, 2, 826-866.
Delang L, Coelmont L, Neyts J. Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010; 2(4):826-866.
Delang, Leen; Coelmont, Lotte; Neyts, Johan. 2010. "Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care." Viruses 2, no. 4: 826-866.